Aadi Bioscience (AADI) – Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Aadi Bioscience (NASDAQ: AADI):

• 8/27/2024 – Aadi Bioscience was downgraded by analysts at Piper Sandler Companies from an “overweight” rating to a “neutral” rating. They now have a $1.75 price target on the stock.
• 8/27/2024 – Aadi Bioscience was downgraded by analysts at Piper Sandler from an “overweight” rating to a “neutral” rating. They now have a $1.75 price target on the stock, down previously from $5.00.
• 8/21/2024 – Aadi Bioscience had its “neutral” rating reaffirmed by analysts at HC Wainwright.
• 8/21/2024 – Aadi Bioscience was downgraded by analysts at Jefferies Financial Group Inc. from a “buy” rating to a “hold” rating. They now have a $1.50 price target on the stock, down previously from $11.00.
• 8/21/2024 – Aadi Bioscience was downgraded by analysts at TD Cowen from a “buy” rating to a “hold” rating.

Aadi Bioscience Trading Down 1.7 %

Aadi Bioscience stock opened at $1.78 on Wednesday. The firm has a market capitalization of $43.71 million, a PE ratio of -0.70 and a beta of 0.69. Aadi Bioscience, Inc. has a 1-year low of $1.21 and a 1-year high of $6.29. The firm’s 50 day simple moving average is $1.55 and its 200 day simple moving average is $1.79.

Aadi Bioscience (NASDAQ:AADI) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.17. The firm had revenue of $6.18 million during the quarter, compared to analyst estimates of $6.33 million. Aadi Bioscience had a negative return on equity of 66.67% and a negative net margin of 274.77%. During the same quarter in the prior year, the firm posted ($0.67) earnings per share. Research analysts forecast that Aadi Bioscience, Inc. will post -2.02 earnings per share for the current year.

Insider Activity

In other news, Chairman Neil Desai sold 31,348 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1.45, for a total transaction of $45,454.60. Following the transaction, the chairman now directly owns 1,260,195 shares of the company’s stock, valued at $1,827,282.75. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold 92,415 shares of company stock worth $144,551 over the last three months. 37.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Aadi Bioscience

Several hedge funds and other institutional investors have recently modified their holdings of AADI. Decheng Capital LLC purchased a new position in Aadi Bioscience in the 4th quarter worth approximately $1,063,000. Marquette Asset Management LLC purchased a new position in Aadi Bioscience during the first quarter valued at $135,000. Acuitas Investments LLC increased its holdings in Aadi Bioscience by 10.8% in the 2nd quarter. Acuitas Investments LLC now owns 352,483 shares of the company’s stock valued at $515,000 after acquiring an additional 34,344 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Aadi Bioscience in the second quarter worth about $37,000. 52.08% of the stock is currently owned by hedge funds and other institutional investors.

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.